Arbor Biotechnologies
Arbor Biotechnologies is a Gene & Genome Editing Platforms company founded in 2016 and based in Cambridge, United States. It has raised $300M in total funding, most recently a Series C in 2025.
Co-founded in 2016 in Cambridge, Massachusetts by Feng Zhang, David Walt, David Scott, and Winston Yan, Arbor Biotechnologies runs a high-throughput discovery platform that searches natural diversity for new gene-editing proteins, then optimizes them into a suite of editors spanning gene knockout, excision, reverse-transcriptase editing, and large gene insertion. Early on, Arbor used the engine to discover Cas13d, a compact RNA-targeting CRISPR enzyme. The company is advancing its lead candidate, ABO-101, for primary hyperoxaluria type 1, and closed a $73.9M Series C in 2025 led by ARCH Venture Partners and TCGX, bringing total capital raised above $300M.
Its discovery engine continuously expands the editing toolkit, including the small enzymes critical for in vivo delivery.
arbor.bio ↗·Gene & Genome Editing Platforms·
United States·private 
